A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.
Also called NCT02963766
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 154 participants
- Sponsor
- Registry
-
NCT02963766 -
2016-000361-22
-
- Other papers using this trial's data
- Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, France, Germany, Hungary, India, Mexico, Puerto Rico, Saudi Arabia, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02963766. Randomized; double masking; primary purpose treatment. Start 2016-12-29 (actual); primary completion 2021-06-12 (actual). Results posted on 2022-07-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
- Acronym
- AWARD-PEDS
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02963766- Content hash
213a01c83f025b24307a51c62490ce1865152f0cd2099b2fa06be13fb313441e